comparemela.com
Home
Live Updates
OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit : comparemela.com
OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
BCVA gains of +5.5 letters at 24 months in Cohort 4 patients
BCVA gains of +7.4 letters among Cohort 4 patients with extensive OpRegen bleb coverage of the GA lesion
Maintenance or increases...
Related Keywords
Israel ,
Jerusalem ,
Israel General ,
United States ,
American ,
David Telander ,
Brianm Culley ,
Roche Group ,
Genentech ,
Foundation Fighting Blindness ,
Exchange Commission ,
Oregon Health Science University Casey Eye Institute ,
Retinal Consultants Medical Group ,
Eterna Therapeutics Inc ,
Lineage Cell Therapeutics Inc ,
Lineage Cell Therapeutics ,
Gene Therapy Innovation ,
Oregon Health ,
Science University Casey Eye ,
Retinal Pigment Epithelium ,
Cell Therapy ,
Geographic Atrophy ,
Early Treatment Diabetic Retinopathy Study ,
Retinal Cell ,
Gene Therapy Innovation Summit ,
Opregen Phase ,
Cell Therapeutics ,
Eterna Therapeutics ,
Annual Report ,
comparemela.com © 2020. All Rights Reserved.